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Abstract
Background: Pregabalin, a g-amino-n-butyric acid derivative, is an antiepileptic drug not yet official in any
pharmacopeia and development of analytical procedures for this drug in bulk/formulation forms is a necessity. We
herein, report a new, simple, extraction free, cost effective, sensitive and reproducible spectrophotometric method
for the determination of the pregabalin.
Results: Pregabalin, as a primary amine was reacted with ninhydrin in phosphate buffer pH 7.4 to form blue violet
colored chromogen which could be measured spectrophotometrically at lmax 402.6 nm. The method was
validated with respect to linearity, accuracy, precision and robustness. The method showed linearity in a wide
concentration range of 50-1000 μgm L
-1 with good correlation coefficient (0.992). The limits of assays detection
was found to be 6.0 μgm L
-1 and quantitation limit was 20.0 μgm L
-1. The suggested method was applied to the
determination of the drug in capsules. No interference could be observed from the additives in the capsules. The
percentage recovery was found to be 100.43 ± 1.24.
Conclusion: The developed method was successfully validated and applied to the determination of pregabalin in
bulk and pharmaceutical formulations without any interference from common excipients. Hence, this method can
be potentially useful for routine laboratory analysis of pregabalin.
Background
Pregabalin (PRG), (S)-3-(aminomethyl)-5-methylhexa-
noic acid (Figure 1), is an antiepileptic and structurally
related to the inhibitory neurotransmitter aminobutyric
acid (GABA) It was recently approved for adjunctive
treatment of partial seizures in adults [1,2] in United
States and Europe and for the treatment of neuropathic
pain from post therapeutic neuralgia and diabetic neuro-
pathy. Currently, there is no official analytical procedure
for pregabalin in any pharmacopeia. Several reports are
there in literature for PRG determination based on chro-
matographic methods, i.e., gas chromatography-mass
spectrophotometry (GC-MS), LC-MS-MS [3,4], HPLC
[5-7] coupled with varying detection techniques like tan-
dem mass spectrometry [8], fluorometry [9] and enan-
t i o s p e c i f i ca n a l y s i s[ 1 0 ] .T h e s em e t h o d sm a yi n v o l v e
procedural variations including pre- and post- column
derivatization [10]. Recently, capillary electrophoresis and
nuclear magnetic resonance technique was reported for
PRG involving complexation with cyclodextrins [11]. All
these are complex trace analysis techniques most of
which have been employed for PRG determination in
biological fluid samples. However, routine analysis of the
drug in bulk powder and pharmaceutical preparations in
research laboratories and pharmaceutical industry
requires a relatively uncomplicated and a more cost
effective method like UV/visible spectrophotometry or
spectrofluorometry. Pregabalin, as such, has a poor UV/
visible absorbance profile (Figure 2) and very few
reported methods have relied on generation of a chromo-
phoric product by reaction of the drug with some suita-
b l er e a g e n t .C o n s i d e r i n gt h el i m i t e dl i t e r a t u r er e p o r t s
a v a i l a b l ei nt h i sa r e a[ 1 2 - 1 4 ] ,w ef o u n di tv e r yp e r t i n e n t
to investigate and develop a novel spectrophotometric
method for determination of pregabalin in bulk powder
and pharmaceutical preparations. Ninhydrin has been
used as a chromogenic agent in spectrophotometric
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The present study describes the evaluation of ninhydrin
as a chromogenic reagent in the development of simple
and a rapid spectrophotometric method for the determi-
nation PGB in its pharmaceutical dosage forms. The pro-
cedure does not involve any extraction step with any
organic solvent and can be directly carried out in phos-
phate buffer pH 7.4 which makes it ideal for routine
analysis of the drug in bulk or in pharmaceutical
formulations.
Results and discussion
Method
In our efforts to design a novel spectrophotometric method
for quantification of pregabalin, we investigated its derivati-
zation with ninhydrin ((triketohydrindene hydrate) for gen-
eration of a chromophoric product. Figure 3 shows the
UV/visible spectrum of the chromophoric derivative. The
procedure involves formation of purple colored product by
reaction of pregabalin with ninhydrin by heating at a tem-
perature of 70-75°C for 20 minutes. Reaction of ninhydrin
1 with amines, alpha amino acids, peptides, and proteins
yields an aldehyde with one carbon atom less than the
alpha-amino acid; and carbon dioxide in stoichlometric
amounts and varying amounts of ammonia, hydrindantin
and a chromophoric compound known as Ruhemann’s
Purple (2-(3-hydroxy-1-oxo-1H-inden-2-ylimino)-2H-
indene-1,3-dione). This pigment serves as the basis of
detection and quantitative estimation of alpha-amino
acids.
13 Mechanism proposed (Figure 4) for the reaction
involves removal of a water molecule from ninhydrin
hydrate 1 to generate 1,2,3-indantrione 2 in the first step,
which then, forms a Schiff’s base with the amino group of
pregabalin resulting in the ketimine 3. Removal of the alde-
hyde RCHO generates an intermediate amine 4 (2-amino-
l,3-indandione). Condensation of this intermediate amine
with another molecule of ninhydrin follows to form the
expected chromophore 5 (Ruhemann’s Purple). The rate-
determining step in the entire sequence of the ninhydrin
reaction is the nucleophilic-type displacement of a hydroxy
group of ninhydrin hydrate by a non-protonated amino
group.
Effect of pH
Of the buffers investigated (acetate buffer, phosphate
buffer), colour development was noted in case of phos-
p h a t eb u f f e r .T h eo p t i m u mb u f f e rp Hw a sf o u n dt ob e
7.4 and lower pH ranges resulted in an insufficient col-
our development.
Effect of reagent concentration
The addition of 1.0 mL of ninhydrin solution (0.2% w/v)
was sufficient to obtain the maximum and reproducible
absorbance values for the various concentration ranges of
PGB. Smaller amounts resulted in incomplete reaction.
Further increase in the concentration had no significant
effect on complex formation, although absorbance
increased slightly owing to the reagent background used.
Effects of temperature and heating time
The effects of temperature and heating time on the for-
mation of the coloured complex were also optimized. At
room temperature, the addition of ninhydrin did not lead
to the formation of any coloured product and higher
temperatures were required to accelerate the reaction.
The colour intensity increased with increasing tempera-
ture and maximum absorbance was obtained following
heating on a water bath at a temperature of 70-75°C for
20 minutes. Further heating caused no appreciable
change in the colour. The complex obtained was highly
stable for more than 6 h.
Validation
The method was validated with respect to linearity and
range, accuracy and precision, limit of detection (LOD)
Figure 1 Chemical structure of pregabalin.
Figure 2 UV/Visible scan of pregabalin without derivatization
(lmax 196.2 nm).
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ness. The developed method was validated for the pure
drug as well as marketed formulation of pregabalin
(Pregabalin 75; Torrent pharmaceuticals) and the var-
ious validation parameters are shown in Table 1.
Linearity and range
The regression plots showed compliance with Beer Lam-
bert’s law (linearity) in the concentration range of 50
μg/mL-1000 μg/mL with a correlation coefficient (r
2)o f
0.992. The standard plot is given in Figure 5. Table 1
summarizes the performance data and statistical
parameters for the proposed method including concen-
tration ranges, linear regression equation, correlation
coefficient, molar absorptivity, Sandell sensitivity limit
and these indicate a good linearity over the working
concentration ranges.
Precision
Precision were investigated by analyzing different con-
centrations of pregabalin (0.2-1.4 mg/mL) in three inde-
pendent replicates on the same day (intra-day precision)
and on three consecutive days (inter-day precision). The
data is represented as relative standard deviation (RSD)
Figure 3 UV/Visible scan of the chromophoric product of pregabalin (lmax 402.6 nm).
Figure 4 Mechanism of generation of chromophore (Ruhemann’s Purple) by reaction of pregabalin with ninhydrin.
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standard deviation (RSD) values for intra- day and inter-
day analysis indicate good precision of the method.
Accuracy
The accuracy of the method signifies the closeness of the
measured value to the true value for the sample. To
determine the accuracy of the proposed method, different
levels of drug concentrations were prepared from inde-
pendent stock solutions and analyzed. To provide an
additional support to the accuracy of the developed assay
method, a standard addition method was employed,
which involved the addition of different concentrations
of pure drug to a known pre analyzed dilution of the
pure drug as well as formulation sample and the total
concentration was determined using the proposed
method. Accuracy was assessed as the percentage relative
error Er and mean % recovery. The percentage recovery
of the added pure drug was calculated as:
% recovery =

(Ct − Ci)/Ca

× 100,
Where
Ct is the total drug concentration measured after stan-
dard addition;
Ci drug concentration in the formulation sample;
Ca, drug concentration added.
The percentage relative error was calculated as: Er %=
[(found - added)/added] × 100
Recovery values from standard addition method fol-
lowed for the bulk drug analysis ranged from 96.5 to
100.3% (Table 3). Recovery studies with marketed for-
mulation returned values ranging from 97.09 to 99.74%
(Table 4).
Interference
Satisfactory values of the mean recovery values ± SD,
RSD % and Er % in recovery studies in drug formulation
(Table 4) revealed that there is no potential interference
of the excipients listed by the manufacturer, i.e., talc,
lactose monohydrate and maize starch. This may be
attributed to the dependence of the reaction in the pro-
posed method on the presence of a primary aliphatic
amino group in the drug molecule which is not present
in any of these excepients.
Limit of detection (LOD) and limit of quantitation (LOQ)
LOD and LOQ of the method were established using
calibration standards (Table 1). LOD and LOQ were cal-
culated as 3.3 s/s and 10 s/s, respectively, as per ICH
definitions, where, s is the mean standard deviation of
replicate determination values under the same condi-
tions as the sample analysis in the absence of the analyte
(blank determination), and s is the sensitivity, namely
the slope of the calibration graphs.
Robustness
Repeatability is based on the results of the method oper-
ating over short interval of time under same conditions.
Robustness was examined by evaluating the small varia-
tions in different experimental conditions such as heat-
ing temperatures (± 2° C), working wavelengths, volume
and concentration of reagents. Three replicate determi-
nations at six different concentration levels of the drugs
were carried out. The within-day RSD values were
Table 1 Validation data for determination of pregabalin
by proposed method
Validation parameter Results
Absorption maximum 402.6 nm
Regression equation y = 1.908x - 0.056
Slope 1.908
Intercept 0.056
Beer’s law limit (μgm L
-1) 50-1000
Molar Absorptivity (L/mol
-1/cm
-1) 1198.4
Sandell’s sensitivity (μg/cm
2/0.001 A.U) 0.1328
Coefficient of correlation(r) 0.992
Limit of detection (LOD) 0.006 mg/mL
Limit of quantification (LOQ) 0.02 mg/mL
Accuracy 100.43 ± 1.24
Precision Intra-day = 0.62
Inter-day = 0.61
Robustness Less than 1%
% Purity 99.8%
Figure 5 Standard plot of pregabalin by ninhydrin method.
Table 2 Precision of the proposed methods for the
analysis of pregabalin
Pregabalin (mg/ml) Within day, n = 3 Between day, n = 3
Mean ± SD RSD (%) Mean ± SD RSD (%)
0.2 0.288 ± 0.14 0.49 0.287 ± 0.0005 0.0020
0.4 0.551 ± 0.28 0.51 0.551 ± 0.0004 0.0007
0.6 0.890 ± 0.42 0.48 0.890 ± 0.0003 0.0004
0.8 1.451 ± 0.56 0.39 1.452 ± 0.0005 0.0004
1.0 1.989 ± 0.71 0.36 1.990 ± 0.0003 0.0002
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method has reasonable robustness.
Stability
The stability of the final sample solutions was examined
by their absorbance values and responses were found to
be stable for at least 6 hours at room temperature.
Analysis of marketed formulation (Pregabalin capsules)
Table 5 gives the results of the assay for pregabalin car-
ried out on marketed formulation by the proposed
method and revealed that there is close agreement
between the results obtained by the proposed methods
and the label claim. The recovered drug content was
found to be 99.48%.
Analytical applications
The results with the proposed method for the determi-
nation of pregabalin in its pharmaceutical formulation
(Pregabalin75 capsules) suggest satisfactory recovery.
Further, standard addition technique followed to check
the validity of the method have given good recoveries of
the drug in presence of formulation suggesting a nonin-
terference from formulation excepients. Hence, this
method can be recommended for adoption in routine
analysis of pregabalin in in quality control laboratories.
Conclusion
The method proposed is simple, rapid, inexpensive and
sensitive for the determination of pregabalin in bulk as
well as in marketed form (capsules). There is no require-
ment of any sophisticated apparatus as in chromato-
graphic methods. Omission of an extraction step with
organic solvents is an added advantage. The method has
been validated in terms of its sensitivity, simplicity,
reproducibility, precision, accuracy and stability of the
coloured species for ≥ 6 h suggesting its suitablility for
the routine analysis of PGB in pure form (in bulk
Table 3 Results of recovery studies with pure drug pregabalin by standard addition method
Initial Conc. (mg/mL) Volume (mL) Amount added (μg) Amount recovered (μg) Recovery (%) ± SD
a RSD (%)
0.2 5.0 100.0 98.7 98.70 ± 0.890 0.91
0.4 5.0 100.0 96.5 96.50 ± 0.923 0.95
0.6 5.0 100.0 99.7 99.70 ± 0.624 0.63
0.8 5.0 100.0 100.3 100.3 ± 1.600 1.57
1.0 5.0 100.0 98.1 98.10 ± 1.718 1.72
a Average of determinations carried out in triplicate.
Table 4 Recovery studies with pregabalin capsules by standard addition method
Initial Conc. (mg/mL) Volume (mL) Amount of PGB added (μg) Amount recovered (μg) Recovery (%) ± SD
a Er% RSD (%)
0.05 5.0 50.0 49.5 98.85 ± 0.145 -1.14 0.14
0.05 5.0 100.0 99.5 99.09 ± 0.370 -0.91 0.37
0.05 5.0 200.0 199.1 99.45 ± 0.124 -0.550 0.13
0.1 5.0 50.0 49.1 98.71 ± 0.471 -1.29 0.47
0.1 5.0 100.0 98.1 98.16 ± 0.271 -1.83 0.28
0.1 5.0 200.0 98.1 98.16 ± 0.271 -1.83 0.28
0.2 5.0 50.0 49.0 98.44 ± 0.426 -1.55 0.43
0.2 5.0 100.0 99.7 99.67 ± 0.186 -0.32 0.19
0.2 5.0 200.0 199.0 99.49 ± 0.165 -0.510 0.17
0.4 5.0 50.0 49.7 99.27 ± 0.251 -0.73 0.25
0.4 5.0 100.0 97.6 97.54 ± 0.196 -2.45 0.20
0.4 5.0 200.0 199.7 99.74 ± 0.123 -0.253 0.12
0.6 5.0 50.0 49.8 99.07 ± 0.483 -0.92 0.48
0.6 5.0 100.0 98.2 98.29 ± 0.134 -1.70 0.14
0.6 5.0 200.0 198.9 98.71 ± 0.646 -1.287 0.65
0.8 5.0 50.0 49.1 98.62 ± 0.479 -1.38 0.48
0.8 5.0 100.0 99.2 99.25 ± 0.098 -0.74 0.10
0.8 5.0 200.0 198.2 99.22 ± 0.136 -0.777 0.14
1.0 5.0 50.0 50.0 99.49 ± 0.495 -0.51 0.49
1.0 5.0 100.0 97.0 97.09 ± 0.147 -2.91 0.15
1.0 5.0 200.0 199.5 99.66 ± 0.198 -0.333 0.20
a Average of determinations carried out in triplicate.
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interference from excipients.
Experimental
Apparatus
All absorption spectra were recorded using a Perkin
Elmer lambda 15 UV-Visible spectrophotometer (Ger-
man) with a scanning speed of 60 nm/min and a band
width of 2.0 nm, equipped with 10 mm matched quartz
cells. A CyberScan pH 510 (Eutech instruments) pH
meter was used for checking the pH of buffer solutions.
Materials and reagents
All chemicals and materials were of analytical grade and
were purchased from Qualigens fine chemicals, Mumbai,
India. All solutions were freshly prepared in double dis-
tilled water.
Pure samples
Pregabalin (PGB) pure grade was graciously provided as
a gift samples by Vardhman Chemtech limited, Dera-
bassi, Punjab, India.
Market samples
Pregabalin75 capsules (label amount 75 mg PGB/Capsule)
Torrent Pharmaceuticals were purchased from the market.
Preparation of phosphate buffer pH 7.4
Phosphate buffer pH 7.4 was prepared by mixing 250
mL of 0.2 M potassium dihydrogen phosphate with
195.5 ml of 0.2 M NaOH and making up the volume to
1000 ml with distilled water. The pH of the buffer was
adjusted to 7.4 using a precalibrated pH meter.
Standard Stock solutions
Stock solution of pregabalin (2 mg/ml) was prepared by
dissolving 200 mg of pregabalin in 100 mL of phosphate
buffer (pH 7.4).
Preparation of ninhydrin solution
The 0.2% solution of ninhydrin was prepared by dissol-
ving 200 mg of ninhydrin in 100 ml of ethanol and was
kept in an amber colored bottle.
Method
Standard plot
Different aliquots were taken from the stock solution
(2 mg/ml) and diluted with phosphate buffer pH 7.4 to
prepare a series of concentrations ranging from 50 to
1000 μg/mL of pregabalin. To 5.0 mL of these aliquots
taken in stoppered tubes, 1.0 mL of ninhydrin solution
(0.2% w/v) was added and heated on a water bath at a
temperature of 70-75°C for 20 minutes. The tubes were
kept covered to avoid the loss of solvent due to evapora-
tion. After cooling the solution to room temperature,
t h ea b s o r b a n c ev a l u e sw e r em e a s u r e di nt r i p l i c a t ea t
402.6 nm against mixture of 5.0 mL phosphate buffer
(pH 7.4) and 1.0 mL 0.2% ninhydrin as reagent blank.
The calibration graph was obtained by plotting the
absorbance values at the lmax of the drug (402.6 nm)
against corresponding concentration values and compli-
ance with Beer Lambert’s law was assessed.
Analysis of pharmaceutical formulation
Preparation of capsule sample solution
The contents of twenty capsules were mixed and weighed
accurately. Separate quantities of the powder equivalent
to 30 mg, 60 mg and 90 mg of PRG were transferred into
a 100 mL volumetric flasks, dissolved in water, and soni-
cated for 5 min., the volume was then completed with
water, shaken well for 5 min. and filtered into a dry flask.
To 5.0 mL aliquots of the filtrate taken in stoppered
tubes, 1.0 mL of ninhydrin solution (2.0% w/v) was added
and solution heated on a water bath at a temperature of
70-75°C for 20 minutes. Solutions were cooled to room
temperature and the absorbance values noted in triplicate
at 402.6 nm against reagent blank.
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